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Abstract
Introduction: Non-steroidal anti-inflammatory drugs and corticosteroids are both used in the
treatment acute gouty arthritis and may adversely interact with colchicine. Gastrointestinal toxicity of
colchicine is dose-dependent and can be aggravated by drug-drug and drug-patient interactions.
Case presentation: Colonic perforation associated with second-line administration of colchicine
for acute gouty arthrtitis was identified in an elderly man with several comorbidities who was also
treated with non-steroidal anti-inflammatory drugs and corticostroids. Underlying diverticular disease
was discovered at the time of surgical therapy.
Conclusions: Initial treatment of acute gouty arthritis with non-steroidal anti-inflammatory drugs
or corticosteroids may increase colchicine toxicity by subsequent pharmacokinetic and
pharmacodynamic interaction in the gut wall. The literature is reviewed suggesting that diverticular
disease should be included in the list of adverse event risk factors when colchicine is being
considered.
Case Presentation
A 74-year-old Caucasian male from Italy with chronic
renal failure, ischemic heart disease, congestive heart
failure, hypertension, diabetes mellitus and a history of
gout presented to the emergency department with acute
left-sided knee pain due to contusion after a recent fall.
Other joints of the left extremity were not affected. After
exclusion of acute hemarthrosis, internal knee derange-
ments and musculotendinous strains by physical exam-
ination and radiograph, he was discharged home with the
knee immobilized with an elastic wrap and crutches for
pain associated with weight bearing. Three days later,
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the ankle of the same leg. Signs of inflammation extended
beyond the confines of the ankle. Acute arthritis was
suspected and, after exclusion of venous thrombosis by
Doppler ultrasound, the patient was admitted for diag-
nostic work-up and treatment. His regular medications
included daily oral carvedilol 18.75 mg, simvastatin
20 mg, ramipril 5 mg, amiodarone 200 mg, metformin
750 mg, omeprazole 20 mg, furosemide 125 mg, and
warfarin 2.5 mg. The patient denied using herbal or over
the counter products. He was independent in activities of
daily living. There was no history of abdominal trauma.
Investigations before final diagnosis included blood and
urine tests that showed elevated uric acid of 12.9 mg/dl
(normal range, 2.5–8.0 mg/dl), mild leukocytosis, ele-
vated erythrocyte sedimentation rate and C-reactive
protein, hyperglycemia, and a reduced glomerular filtra-
tion rate of 34 ml/min; blood cultures were negative, liver
function tests, amylase and serial troponins were normal.
Knee radiographs excluded signs of stress fracture or
traumatic process on bone or joint. A chest radiograph
demonstrated signs of congestive heart failure; serial
electrocardiograms confirmed atrial fibrillation but did
not show signs of myocardial ischemia. Gouty ankle
arthritis was diagnosed without joint aspiration; 100 mg
diclofenac were administered for pain relief, metformin
was stopped and normal saline was infused because of
preexisting stage 3 moderate renal insufficiency. With no
beneficial effect after 24 hours, the patient received
second-line therapy with 1 mg colchicine orally. How-
ever, because of gastrointestinal toxicity, colchicine was
stopped after the first dose. Instead, oral prednisone 40
mg/day was administered for three days and was
effective.
Transient oliguric acute renal failure observed during the
course of steroid treatment was interpreted as a side effect
of NSAID aggravated by colchicine (rise in creatinine value
from 2.4 to 5.2 mg/dL; normal range 0.5–1.4. mg/dL).
During resolution of acute renal failure over the following
four days, atypical chest and upper abdominal pain
developed with worsening leukocytosis (rise of white
blood cell count from 10,600/µL to 15,400/µL mg/dL;
normal range 4,800–10,800/µL). With abdominal ultra-
sound showing a small amount of ascites and finally free
air visible in abdominal radiograph, colonic perforation
was diagnosed. Underlying diverticular disease was
discovered at the time of surgical therapy consisting of
resection and temporary colostomy. The postoperative
clinical course was uneventful with no infectious compli-
cations other than peritoneal irritation. Allopurinol at a
dose of 300 mg daily was prescribed for symptomatic
hyperuricemia at 6 weeks after completion of surgical
treatment.
Discussion
NSAIDs and corticosteroids are both used in the treatment
acute gouty arthritis and may adversely interact with
colchicine. Gastrointestinal toxicity of colchicine is dose-
dependent and can be aggravated by drug-drug and drug-
patient interactions. The risk of colonic perforation may
relate to intracolonic pressure and mucosal barrier
function in the wall of diverticula [1]. The administration
of NSAIDs, opioids, and corticosteroids for the treatment
of arthritis is associated with an increased risk of colonic
diverticular perforation [2]. NSAIDs and corticosteroids
are indicated for arthritis; these two classes of drugs as well
as colchicine are frequently used to treat and prevent
recurrence of acute gout [3]. The maximum dose of
colchicine for treating an acute attack of gout should be
6 mg because of its narrow therapeutic window, with dose-
limiting gastrointestinal side-effects such as diarrhoea and
vomiting [4]. Colchicine toxicity relates to its cellular anti-
mitotic action and preferentially affects tissues that have a
rapid turnover including the gastrointestinal tract [5]. As
colchicine increases intracolonic pressure and impairs
mucosal barrier functions [6], it may increase the risk of
developing perforation. Colonic perforation in asympto-
matic diverticulosis related to colchicine has not yet been
reported.
Colchicine, long used to treat gout, arrests microtubule
assembly and inhibits many cellular functions [7]. In
addition to its use in gout, it has also been recommended
in preventing attacks of familial Mediterranean fever, and
in the treatment of primary biliary cirrhosis, amyloidosis,
and condyloma acuminata [8, 10]. At micromolar
concentrations, it suppresses monosodium urate crystal-
induced NACHT-LRR-PYD-containing protein-3 (NALP3)
inflammasome-driven caspase-1 activation, IL-1beta pro-
cessing and release, and L-selectin expression on neutro-
phils; at nanomolar concentrations, colchicine blocks the
release of a crystal-derived chemotactic factor from
neutrophil lysosomes, blocks neutrophil adhesion to
endothelium by modulating the distribution of adhesion
molecules on the endothelial cells, and inhibits mono-
sodium urate crystal-induced production of superoxide
anions from neutrophils [7]. Trial evidence supports its
efficacy in acute gout and in preventing gout flares, but it
has narrow therapeutic index, and overdosage isassociated
with gastrointestinal, hepatic, renal, neuromuscular, and
cerebral toxicity, bone marrow damage, and high
mortality [11].
Colchicine, which is increasingly considered third-line
therapy only after NSAIDs and corticosteroids in patients
at risk according to current guidelines, should be taken at
an initial dose of 1 mg followed by 1 tablet every 2 hours
until the gouty pain is relieved, gastrointestinal symptoms
develop, or the maximum dose is reached; in elderly
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co-existing renal or hepatic disease, alternative therapy
should be used or a maximum dose should not exceed
3 mg colchicine [12]. This dosage advice for colchicine has
been amended recently, coinciding with the introduction
of a 0.5 mg strength tablet. For otherwise healthy adults,
the dosing interval has been increased from 2 hours to
6 hours, with a maximum dose of 2.5 mg in the first
24 hours and a maximum cumulative dose of 6 mg over
four days. In elderly patients, patients with renal or hepatic
impairment, and patients weighing less than 50 kg, other
treatments should be considered or lower doses of
colchicine used [12]. Patients should be warned of the
symptoms of colchicine toxicity and advised to discon-
tinue therapy immediately if they occur [3].
In our patient, low-dose colchicine was started as second
line therapy and with the oral administration of a 1 mg
tablet because 0.5-mg tablets are not yet available in Italy.
Various factors may then have additionally modified
toxicity of colchicine. (a) Colchicine is rapidly absorbed
from the gastrointestinal tract after ingestion. It undergoes
significant first-pass hepatic metabolism, which primarily
involves deacetylation. Subsequent to this, the metabolites
undergo widespread enterohepatic recirculation before
being excreted in bile and faeces [7]. It is thought that the
extended time period during which the gastrointestinal
mucosal cells are exposed to colchicine may explain the
prominence of the gastrointestinal symptoms of toxicity.
(b) Renal clearance also accounts for 10–20% of
colchicine removal and if renal function is normal, larger
fractions can be excreted via this route if a toxic amount
has been ingested. Moderate renal dysfunction may,
thus, have increased enterohepatic colchicine levels [12].
(c) Increased urinary excretion also occurs in the presence
of hepatic disease, as there is a reduction in the capacity for
deacetylation; and, if renal and hepatic diseases coexist,
the possibility of toxicity greatly increases [13]. Hepatic
function was normal in our patient making it unlikely
that such a mechanism contributed to increased toxicity.
(d) Cytochrome P450 3A4 and the drugs that bind to it
influence colchicine’s pharmacokinetics and pharmaco-
dynamics; CYP3A4 inhibitors may increase the levels/
effects of colchicine. Diclofenac administered as first-line
treatment for the patient’s acute gout and, more impor-
tantly, amiodarone which the patient had taken chroni-
cally inhibit CYP3A4 [14] and, therefore, may have
augmented toxicity. (e) The multidrug transporter P-
glycoprotein, and drugs that bind to it, may also affect
colchicine pharmacology: P-glycoprotein is an ATP-
dependent phospho-glycoprotein that is located in the
cell membrane and interacts with various drugs. When
binding drugs are prescribed in combination, changes in
P-glycoprotein activity may lead to intracellular accumula-
tion of colchicine; this list of drugs includes prednisolone
[15] which was administered as third-line therapy of acute
Table 1. Naranjo ADR Probability Scale. The use of the scale involves answering a series of questions about the adverse event, and then calculating a final
score that provides some indication of the overall probability that the adverse event represents an adverse reaction to a drug
1 Are there previous conclusive reports on this reaction?
Yes (+1) No (0) Don’t know (0) +1*
2 Did the adverse event appear after the suspected drug was administered?
Yes (+2) No (−1) Don’t know (0) +2
3 Did the adverse reaction improve when the drug was discontinued, or a specific antagonist was administered?
Yes (+1) No (0) Don’t know (0) 0
4 Did the adverse reaction reappear when the drug was readministered?
Yes (+2) No (−1) Don’t know (0) 0
5 Are there alternative causes (other than the drug) that could on their own have caused the reaction?
Yes (−1) No (+2) Don’t know (0) -1
6 Did the reaction reappear when a placebo was given?
Yes (−1) No (+1) Don’t know (0) 0
7 Was the drug detected in the blood (or other fluids) in concentrations known to be toxic?
Yes (+1) No (0) Don’t know (0) 0
8 Was the reaction more severe when the dose increased, or less severe when dose was decreased?
Yes (+1) No (0) Don’t know (0) 0
9 Did the patient have a similar reaction to the same or similar drug in any previous exposure?
Yes (+1) No (0) Don’t know (0) 0
10 Was the adverse event confirmed by any objective evidence?
Yes (+1) No (0) Don’t know (0) +1
Total +3
The final score allows some basis for an objective assessment of the likelihood that an ADR may have occurred:
> 9 = highly probable.
>5− 8 = probable.
>1− 4 = possible.
≤ 0 = doubtful.
*Answers given for the patient reported.
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pharmacodynamic factors therefore may well have
increased the gastrointestinal toxicity of colchicine.
The adverse gastrointestinal event of colonic perforation
likely relates to previously undiagnosed diverticular
disease. In the Naranjo Adverse Drug Reaction Probability
Scale [16], a score of +3 indicates the overall probability
that the adverse event represents an adverse reaction to
colchicine as “possible” (Table 1). Drug-Drug and drug-
patient interaction likely have contributed to the treat-
ment’s complication. As intracolonic pressure plays a
prominent role in macroscopic perforation of colonic
diverticular disease [2], its augmentation during diarrhea
of colchicine’s gastrointestinal toxicity may give this drug a
predominant causative role.
In conclusion, drug treatment of acute gouty arthritis with
NSAID and corticosteroids may have increased colchicine
toxicity by pharmacokinetic and pharmacodynamic inter-
action in the wall of diverticula. Increased intracolonic
pressure of colchicine-induced diarrhoea was possibly
contributing to the patient’s colonic perforation. In
patients with risk factors for colonic perforation including
age, renal insufficiency, NSAIDs and corticosteroids
colchicine should best be avoided. Patients receiving
therapy with colchicine, especially those with renal
comorbidities and concomitant drug treatment, should
be carefully monitored for complications of colchicine’s
gastrointestinal side effects. Oral colchicine formulations
with 0.5-mg tablets should be made available more
widely. Diverticular disease should be included in the
list of adverse event risk factors when therapy with
colchicine is under consideration. Colchicine possibly is
associated with an increased risk of colonic diverticular
perforation.
List of abbreviations
NSAIDs: Non-steroidal anti-inflammatory drugs; NALP3,
NACHT-LRR-PYD-containing protein-3; ATP, Adenosine
triphosphate.
Consent
Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Competing interests
The authors declare that they have competing interests.
Authors’ contribution
BZ, JW and CJW were involved in writing the paper with
data collection and literature search. AK, PP, GS, registrars
involved in treating the patient and data collection. IS and
HP, consultants involved in treating the patient.
Acknowledgement
We thank Rajam Csordas for critical reading of the
manuscript.
References
1. Morris CRHI, Stebbings WSL, Speakman CTM, Kennedy HJ, Hart AR:
Epidemiology of perforated colonic diverticular disease.
Postgrad Med J. 2002, 78:654-659.
2. Piekarek K, Israelsson LA: Perforated colonic diverticular
disease: the importance of NSAIDs, opioids, corticosteroids,
and calcium channel blockers. Int J Colorectal Dis. 2008,
23:1193-1197.
3. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P,
et al.: EULAR Standing Committee for International Clinical
Studies Including Therapeutics. EULAR evidence based
recommendations for gout. Part II: Management. Report
of a task force of the EULAR Standing Committee
for International Clinical Studies Including Therapeutics
(ESCISIT). Ann Rheum Dis. 2006, 65:1312-1324.
4. Morris I, Varughese G, Mattingly P: Colchicine in acute gout. BMJ.
2003, 327:1275-1276.
5. Stemmermann GM, Hayashi T: Colchicine intoxication: a reap-
praisal of its pathology, based on a study of three fatal cases.
Hum Pathol. 1972, 2:321-331.
6. Torbenson M, Montgomery EA, Iacobuzio-Donahue C, Yardley JH,
Wu TT, Abraham SC: Colchicine effect in a colonic hyperplastic
polyp. A lesion mimicking serrated adenoma. Arch Pathol Lab
Med. 2002, 126:615-617.
7. Nuki G: Colchicine: its mechanism of action and efficacy
in crystal-induced inflammation. Curr Rheumatol Rep. 2008,
10:218-227.
8. Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, Gafni J: A
controlled trial of colchicine in preventing attacks of familial
mediterranean fever. N Engl J Med. 1974, 291:932-934.
9. Oo YH, Neuberger J: Options for treatment of primary biliary
cirrhosis Drugs, 2004, 64:2261-2271.
10. Cohen AS, Rubinow A, Anderson JJ, Skinner M, Mason JH, Libbey C,
Kayne H: Survival of patients with primary (AL) amyloidosis.
Colchicine-treated cases from 1976 to 1983 compared with
cases seen in previous years (1961 to 1973). Am J Med. 1987,
82:1182-1190.
11. Terkeltaub RA: Colchicine Update: 2008. Semin Arthritis
Rheum. 2008 Oct 28. [Epub ahead of print].
12. Hood RL, Colchicine poisoning. J Emerg Med. 1994, 12:171-177.
13. Borron SW, Scherrmann JM, Baud FJ: Markedly altered colchicine
kinetics in a fatal intoxication: Examination of contributing
factors Hum Exp Toxicol 1996, 15:885-890.
14. Tang W: The metabolism of diclofenac–enzymology and
toxicology perspectives. Curr Drug Metab 2003, 4:319-329.
15. Niel E, Scherrmann JM: Colchicine today. Joint Bone Spine, 2006,
73:672-678.
16. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al:
A method for estimating the probability of adverse drug
reactions. Clin Pharmacol Ther 1981, 30:239-245.
Page 4 of 4
(page number not for citation purposes)
Cases Journal 2009, 2:6602 http://casesjournal.com/casesjournal/article/view/2/4/6602